Slide 1: Transforming Discovery of Therapeutics and Materials
Transforming Discovery of Therapeutics and Materials May 4, 2023
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this
Slide 3: Schrödinger's Balanced Business Model
Schrödinger’s Balanced Business Model SOFTWARE LICENSING COLLABORATIONS • Life Sciences • Materials Design PROPRIETARY PIPELINE • Drug Design ~1,750 customers worldwide* • Materials Design • Drug Discovery & Development • Wholly-owned or Partnered 14 active projects • 18 active programs TECHNOLOGY P
Slide 4: Recent Business Highlights
Recent Business Highlights • Initiated dosing in Phase 1 study in patients with advanced B cell malignancies SGR-1505 • Initiated dosing in Phase 1 study in healthy subjects SGR-2921 • On track for IND submission in 1H23 • SOS1 program advanced to development candidate status and transitioned to BMS
Slide 5: Long-Term Quarterly Revenue Trend
Long-Term Quarterly Revenue Trend 1Q23 Revenue Highlights • Total revenue +33% YoY • Software revenue comparable YoY • 1Q22 included multi-year agreements that were not up for renewal in 1Q23 • Drug discovery revenue +109% YOY as a result of progress across collaborative pipeline, including $25M mil
Slide 6: Positive Four-Quarter Trailing Average Quarterly Revenue Trend
Positive Four-Quarter Trailing Average Quarterly Revenue Trend 6
Slide 7: 1Q23 Financial Highlights vs. 1Q22
1Q23 Financial Highlights vs. 1Q22 Three Months Ended March 31 2022 2023 % Change (in millions) Total revenue $48.7 $64.8 33% Software revenue $33.1 $32.2 (3%) Drug discovery revenue $15.6 $32.6 109% Gross profit $28.0 $45.7 63% Software gross margin 77% 78% Operating expenses $56.6 $76.2 35% Other
Slide 8: 2023 Financial Guidance Unchanged
2023 Financial Guidance Unchanged (as of May 4, 2023) Expectation FY22 Actual Year-to-Date 1Q23 FY23 Guidance* Total revenue $181.0 $64.8 – Software revenue $135.6M $32.2M 13% - 17% Drug discovery revenue $45.4M $32.6M $70-90M Similar to revenue Operating expense growth 40% 35% growth Software gross
Slide 9: Platform Validated by Advancing Collaboration Programs
Platform Validated by Advancing Collaboration Programs(1)(2) FDA FDA PROGRAM Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved PROGRAM Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved TIBSOVO* CNS IDHIFA* Autoimmune Disease Oncology Oncology Oncology Pulmonary Arterial Hypertension Antifu
Slide 10: Retained and Partnered Proprietary Programs
Retained and Partnered Proprietary Programs PROGRAM DISCOVERY PRECLINICAL PHASE I PROGRAM DISCOVERY PRECLINICAL CLINICAL RIGHTS SGR-1505 (MALT1) SOS1 Relapsed / Resistant RAS-Mutant Cancers Non-Hodgkin’s Lymphoma Undisclosed SGR-2921 (CDC7) Oncology Hematological Cancers and Solid Tumors Undisclosed
Slide 11: Advancing Programs with Breakthrough Potential
Advancing Programs with Breakthrough Potential Status and anticipated next steps SGR-1505 (MALT1) IND-enabling studies • Clinically validated target for underway for leukemias and lymphomas SGR-2921 • Strong single agent and Submit IND and in combination activity in 1H23; Initiate Phase 1 preclinica
Slide 12: Advancing Programs with Breakthrough Potential
Advancing Programs with Breakthrough Potential Status and anticipated next steps SGR-1505 (MALT1) SGR-2921 (CDC7) IND-enabling studies • Clinically validated target for • Key cell cycle checkpoint for underway for leukemias and lymphomas DNA repair SGR-2921 • Strong single agent and • Active as mono
Slide 13: Advancing Programs with Breakthrough Potential
Advancing Programs with Breakthrough Potential Status and anticipated next steps SGR-1505 (MALT1) SGR-2921 (CDC7) SGR-3515 (Wee1) IND-enabling studies • Clinically validated target for • Key cell cycle checkpoint for DNA underway • Therapeutic foracross a potential leukemias and lymphomas repair bro
Slide 14: Upcoming Milestones
Upcoming Milestones • Advance SGR-1505 (MALT1) Phase 1 development • Submit IND for SGR-2921 (CDC7) • Advance IND-enabling studies for SGR-3515 (Wee1) • Advance LRRK2 program • Disclose additional proprietary programs • Leverage new structural biology capabilities 14
Slide 15: Summary
Summary Strong 1Q23 performance Progressing portfolio of collaborative and proprietary programs Balanced business model with multiple value-creation opportunities SOFTWARE LICENSING COLLABORATIONS PROPRIETARY PIPELINE Steady revenue growth Inflecting revenue growth TECHNOLOGY PLATFORM 15
Slide 16: Transforming Discovery of Therapeutics and Materials
Transforming Discovery of Therapeutics and Materials May 4, 2023